Analyst Viewpoint
Rise in prevalence of allergies is driving the global market. Changing lifestyles, environmental exposure, genetics, and urbanization have increased the incidence of asthma, allergic rhinitis, and food allergies across the world. Surge in awareness among healthcare providers about the benefits of allergy immunotherapy as a long-term treatment option is fueling market progress. Furthermore, rise in healthcare expenditure is expected to bolster the global allergy immunotherapy market size during the forecast period.
Increase in investment in R&D on new treatments offers lucrative opportunities to market players. Leading companies are focusing on development of drugs with enhanced efficacy in order to increase market revenue.
Allergy immunotherapy, also known as allergen immunotherapy or allergy shots, is a medical treatment that desensitizes a person’s immune system to specific allergens, which are substances that trigger an allergic reaction.
It is a long-term treatment, which involves increasing and repetitive doses of the allergen to a person over a period of time. The concept behind allergy immunotherapy is to gradually and carefully expose the immune system to the allergen so that the body can develop a tolerance to it. This could lessen the sensitivity of the individual's immune system to the allergen, which can lessen or even eliminate allergic symptoms.
The cost of immunotherapy varies depending on the type (subcutaneous immunotherapy or sublingual immunotherapy), duration, and frequency of treatment, as well as geographical location and healthcare settings. Moreover, allergy immunotherapy requires repeated doses over a longer period of time, which can be costly. Thus, high cost of immunotherapy is one of the barriers for certain patients with less income or insufficient insurance coverage.
Surge in prevalence of allergies among individuals across the world owing to lifestyles changes, environmental exposure, genetics, and urbanization; and increase in exposure to various allergens such as molds, dust mites, and pollens, causing allergies are bolstering the global industry growth.
The various types of allergy immunotherapy are Subcutaneous Immunotherapy (SCIT), which is administered by injecting beneath the skin, Sublingual Immunotherapy (SLIT), which is administered by small doses under the tongue instead of injecting beneath the skin, and home allergy shots, which can be self-administered at home by a patient.
SCIT is a long-term treatment that reduces the severity of symptoms and treats the allergy. Immunotherapy for allergic rhinitis prevents the emergence of asthma in young patients. According to the American Academy of Allergy Asthma & Immunology (2023), 10% to 30% of the global population suffers from allergic rhinitis.
Antihistamines are a class of drugs commonly used to treat symptoms of allergies. These drugs help treat conditions caused by too much histamine, a chemical created by the body’s immune system.
Antihistamines immunotherapy is advised for people who have allergic reactions to pollen and other allergens. It is also used to treat other conditions such as asthma, stomach problems, colds, and anxiety.
The frequency of allergies in developing and developed countries is rising at an exponential rate. This is propelling allergy immunotherapy market demand. In 2023, the Centers for Disease Control and Prevention estimated that about 25.7% of American adults (18 years of age and over) have seasonal allergies, accounting for nearly 31.8% of the adult population.
Rise in spending on healthcare is leading to greater emphasis on novel and efficient treatment approaches, especially for conditions such as allergies. It is likely to make immunotherapy more accessible to everyone. This is anticipated to propel the global allergy immunotherapy market share.
In 2022, according to the Ministry of Finance's annual report, the Economic Survey, public spending on healthcare in India was 2.1% of GDP in 2021-2022 compared to 1.8% in 2020-2021.
A survey of international medical insurers was carried out by the British-American insurance services provider Willis Towers Watson Public Limited Company in 2023. The survey found that the cost of healthcare benefits grew from 8.2% in 2021 to 8.8% in 2022, and is expected to reach 10% by 2023. Thus, the industry is expected to grow at a rapid pace during the forecast period.
Furthermore, combined efforts of major manufacturers and government organizations to promote allergy immunotherapy and create new products to fulfill growing consumer demand are anticipated to contribute to the allergy immunotherapy market growth.
In 2021, Vimian Group signed an agreement to develop new vaccines for allergy and atopic dermatitis together with Angany (Canadian Biotechnology Company).
According to allergy immunotherapy market trends, Europe accounted for the largest share of the global industry in 2022. This is ascribed to high awareness, increase in funding for research & development, favorable medical reimbursement policies, and rise in number of people with allergies.
According to estimates, over 150 million people worldwide are affected by chronic food allergies, which currently affects 20% of the local population of Europe, according to the European Academy of Allergy and Clinical Immunology (EAACI).
The allergy immunotherapy industry in Europe is also driven by rise in R&D costs to produce immunotherapies for other allergy types such as food allergies and insect allergies and availability of appropriate funding for therapy.
According to allergy immunotherapy market analysis, Asia Pacific is expected to experience robust growth during the forecast period. Surge in number of patients with allergies, shift in focus of major players toward increasing presence in the region, and rise in awareness among the population about managing allergies are propelling market development.
For instance, ALK-Abello received regulatory permission from China and subsequently submitted a registration application for sublingual allergy immunotherapy in March 2022. Such initiatives are anticipated to strengthen the market in Asia Pacific.
Leading players are focusing on strategies such as new product launches and investment in research & development of new drugs. These companies are following the latest allergy immunotherapy market trends to boost revenue.
ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck KGaA, Aimmune Therapeutics, Carcassia, Anergis, and Biomay AG are the prominent players in the global industry.
Each of these companies has been profiled in the allergy immunotherapy market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 2.4 Bn |
| Forecast (Value) in 2031 | US$ 5.6 Bn |
| Growth Rate (CAGR) | 9.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 2.4 Bn in 2022
It is anticipated to grow at a CAGR of 9.6% from 2023 to 2031
Rise in prevalence of allergies and increase in healthcare expenditure.
The subcutaneous immunotherapy (SCIT) segment held the largest share in 2022.
Europe was leading region in 2022
ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck KGaA, Aimmune Therapeutics, Carcassia, Anergis, and Biomay AG.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Allergy Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Allergy Immunotherapy Market Analysis and Forecast, 2017–2031
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry
6. Global Allergy Immunotherapy Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Subcutaneous Immunotherapy (SCIT)
6.3.2. Sublingual Immunotherapy (SLIT)
6.4. Market Attractiveness Analysis, by Treatment
7. Global Allergy Immunotherapy Market Analysis and Forecast, by Allergy Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Allergy Type, 2017–2031
7.3.1. Allergic Rhinitis
7.3.2. Asthma
7.3.3. Food Allergy
7.3.4. Venom Allergy
7.3.5. Others
7.4. Market Attractiveness Analysis, By Allergy Type
8. Global Allergy Immunotherapy Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies & Drug Stores
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, By Distribution Channel
9. Global Allergy Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Allergy Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2017–2031
10.2.1. Subcutaneous Immunotherapy (SCIT)
10.2.2. Sublingual Immunotherapy (SLIT)
10.3. Market Value Forecast, by Allergy Type, 2017–2031
10.3.1. Allergic Rhinitis
10.3.2. Asthma
10.3.3. Food Allergy
10.3.4. Venom Allergy
10.3.5. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies & Drug Stores
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Allergy Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Allergy Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Subcutaneous Immunotherapy (SCIT)
11.2.2. Sublingual Immunotherapy (SLIT)
11.3. Market Value Forecast, by Allergy Type, 2017–2031
11.3.1. Allergic Rhinitis
11.3.2. Asthma
11.3.3. Food Allergy
11.3.4. Venom Allergy
11.3.5. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies & Drug Stores
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Allergy Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Allergy Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Subcutaneous Immunotherapy (SCIT)
12.2.2. Sublingual Immunotherapy (SLIT)
12.3. Market Value Forecast, by Allergy Type, 2017–2031
12.3.1. Allergic Rhinitis
12.3.2. Asthma
12.3.3. Food Allergy
12.3.4. Venom Allergy
12.3.5. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies & Drug Stores
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Allergy Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Allergy Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Subcutaneous Immunotherapy (SCIT)
13.2.2. Sublingual Immunotherapy (SLIT)
13.3. Market Value Forecast, by Allergy Type, 2017–2031
13.3.1. Allergic Rhinitis
13.3.2. Asthma
13.3.3. Food Allergy
13.3.4. Venom Allergy
13.3.5. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies & Drug Stores
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Allergy Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Allergy Immunotherapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Subcutaneous Immunotherapy (SCIT)
14.2.2. Sublingual Immunotherapy (SLIT)
14.3. Market Value Forecast, by Allergy Type, 2017–2031
14.3.1. Allergic Rhinitis
14.3.2. Asthma
14.3.3. Food Allergy
14.3.4. Venom Allergy
14.3.5. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies & Drug Stores
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment
14.6.2. By Allergy Type
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. ALK-Abello A/S
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Treatment Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Allergy Therapeutics
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Treatment Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Stallergenes Greer
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Treatment Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. HAL Allergy Group
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Treatment Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. DBV Technologies
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Treatment Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Merck KGaA
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Treatment Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Aimmune Therapeutics
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Treatment Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Carcassia
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Treatment Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Anergis
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Treatment Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Biomay AG
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Treatment Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
List of Figures
Figure 01: Global Allergy Immunotherapy Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Allergy Immunotherapy Market Value Share, by Treatment, 2022
Figure 03: Global Allergy Immunotherapy Market Value Share, by Distribution Channel, 2022
Figure 04: Global Allergy Immunotherapy Market Value Share, by Region, 2022
Figure 05: Global Allergy Immunotherapy Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 06: Global Allergy Immunotherapy Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 07: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Silicone, 2017–2031
Figure 08: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Polyolefins, 2017–2031
Figure 9: Global Allergy Immunotherapy Market Value Share Analysis, by Allergy Type, 2022 and 2031
Figure 10: Global Allergy Immunotherapy Market Attractiveness Analysis, by Allergy Type, 2023–2031
Figure 11: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Allergic Rhinitis, 2017–2031
Figure 12: Global Allergy Immunotherapy Market Revenue (US$ Mn), Asthma, 2017–2031
Figure 13: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Food Allergy, 2017–2031
Figure 14: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Venom Allergy, 2017–2031
Figure 15: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Others, 2017–2031
Figure 16: Global Allergy Immunotherapy Market Value Share Analysis, by Distribution Channel, 2017–2031
Figure 17: Global Allergy Immunotherapy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 18: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 19: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Retail Pharmacies & Drug Stores, 2017–2031
Figure 20: Global Allergy Immunotherapy Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 21: Global Allergy Immunotherapy Market Value Share Analysis, by Region, 2022 and 2031
Figure 22: Global Allergy Immunotherapy Market Attractiveness Analysis, by Region, 2023–2031
Figure 23: North America Allergy Immunotherapy Market Value (US$ Mn) Forecast, 2017–2031
Figure 24: North America Allergy Immunotherapy Market Value Share Analysis, by Country, 2022 and 2031
Figure 25: North America Allergy Immunotherapy Market Attractiveness Analysis, by Country, 2023–2031
Figure 26: North America Allergy Immunotherapy Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 27: North America Allergy Immunotherapy Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 28: North America Allergy Immunotherapy Market Value Share Analysis, by Allergy Type, 2022 and 2031
Figure 29: North America Allergy Immunotherapy Market Attractiveness Analysis, by Allergy Type, 2023–2031
Figure 30: North America Allergy Immunotherapy Market Value Share Analysis (US$ Mn), by Distribution Channel, 2017–2031
Figure 31: North America Allergy Immunotherapy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 32: Europe Allergy Immunotherapy Market Value (US$ Mn) Forecast, 2017–2031
Figure 33: Europe Allergy Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 34: Europe Allergy Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 35: Europe Allergy Immunotherapy Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 36: Europe Allergy Immunotherapy Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 37: Europe Allergy Immunotherapy Market Value Share Analysis, by Allergy Type, 2022 and 2031
Figure 38: Europe Allergy Immunotherapy Market Attractiveness Analysis, by Allergy Type, 2023–2031
Figure 39: Europe Allergy Immunotherapy Market Value Share Analysis, by Distribution Channel, 2017–2031
Figure 40: Europe Allergy Immunotherapy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 41: Asia Pacific Allergy Immunotherapy Market Value (US$ Mn) Forecast, 2017–2031
Figure 42: Asia Pacific Allergy Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 43: Asia Pacific Allergy Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 44: Asia Pacific Allergy Immunotherapy Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 45: Asia Pacific Allergy Immunotherapy Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 46: Asia Pacific Allergy Immunotherapy Market Value Share Analysis, by Allergy Type, 2022 and 2031
Figure 47: Asia Pacific Allergy Immunotherapy Market Attractiveness Analysis, by Allergy Type, 2023–2031
Figure 48: Asia Pacific Allergy Immunotherapy Market Value Share Analysis, by Distribution Channel, 2017–2031
Figure 49: Asia Pacific Allergy Immunotherapy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 50: Latin America Allergy Immunotherapy Market Value (US$ Mn) Forecast, 2017–2031
Figure 51: Latin America Allergy Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 52: Latin America Allergy Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 53: Latin America Allergy Immunotherapy Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 54: Latin America Allergy Immunotherapy Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 55: Latin America Allergy Immunotherapy Market Value Share Analysis, by Allergy Type, 2017–2031
Figure 55: Latin America Allergy Immunotherapy Market Attractiveness Analysis, by Allergy Type, 2023–2031
Figure 54: Latin America Allergy Immunotherapy Market Value Share Analysis, by Distribution Channel, 2017–2031
Figure 55: Latin America Allergy Immunotherapy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 56: Middle East & Africa Allergy Immunotherapy Market Value (US$ Mn) Forecast, 2017–2031
Figure 57: Middle East & Africa Allergy Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Middle East & Africa Allergy Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 59: Middle East & Africa Allergy Immunotherapy Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 60: Middle East & Africa Allergy Immunotherapy Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 61: Middle East & Africa Allergy Immunotherapy Market Value Share Analysis, by Allergy Type, 2017–2031
Figure 62: Middle East & Africa Allergy Immunotherapy Market Attractiveness Analysis, by Allergy Type, 2023–2031
Figure 63: Middle East & Africa Allergy Immunotherapy Market Value Share Analysis, by Distribution Channel, 2017–2031
Figure 64: Middle East & Africa Allergy Immunotherapy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
List of Tables
Table 01: Global Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 01: Global Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Allergy Type, 2017–2031
Table 02: Global Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 07: North America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Allergy Type, 2017–2031
Table 08: North America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 11: Europe Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Europe Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Allergy Type, 2017–2031
Table 13: Asia Pacific Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 15: Asia Pacific Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Allergy Type, 2017–2031
Table 16: Asia Pacific Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 19: Latin America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Allergy Type, 2017–2031
Table 20: Latin America Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 23: Middle East & Africa Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Allergy Type, 2017–2031
Table 24: Middle East & Africa Allergy Immunotherapy Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Allergy Immunotherapy Market
*86 figures and 60 tables includes